Clinical Therapeutics

Top Research Topics at Clinical Therapeutics?

Clinical Therapeutics mainly tackles studies in Internal medicine, Pharmacology, Anesthesia, Surgery and Tolerability. The studies on Internal medicine discussed can also contribute to research in the domains of Gastroenterology and Endocrinology. The Endocrinology study tackling the subject of Diabetes mellitus is the focus of the journal.

Type 2 diabetes is a primary topic of Diabetes mellitus research in the journal. Pharmacokinetics is a focus of the presented Pharmacology works and it dives deep in Pharmacokinetics. While Pharmacokinetics is the focus of it, it also provided insights into the studies of Crossover study, Bioavailability and Dosing.

The research on Anesthesia tackled can also make contributions to studies in the areas of Placebo and Blood pressure. The Surgery study featured in it draws parallels with the field of Antibacterial agent. The Clinical trial study tackled is a key component of adjacent topics in the area of Intensive care medicine.

• Internal medicine (36.21%)
• Pharmacology (15.00%)
• Anesthesia (14.91%)

What are the most cited papers published in the journal?

• A systematic review of the associations between dose regimens and medication compliance (1967 citations)
• Methods for Measuring and Monitoring Medication Regimen Adherence in Clinical Trials and Clinical Practice (721 citations)
• Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity (519 citations)

Research areas of the most cited articles at Clinical Therapeutics:

The journal articles primarily focus on research topics in Internal medicine, Tolerability, Placebo, Surgery and Anesthesia. Aside from discussions in Internal medicine, the most cited articles also deal with the subject of Diabetes mellitus which intersects with Insulin disciplines. The most cited publications tackle topics on Tolerability, which can potentially contribute to the wider field of Pharmacology.

What topics the last edition of the journal is best known for?

• Internal medicine
• Disease
• Diabetes mellitus

The previous edition focused in particular on these issues:

Clinical Therapeutics explores disciplines such as Internal medicine, Adverse effect, Tolerability, Coronavirus disease 2019 (COVID-19) and Randomized controlled trial. The studies in Internal medicine featured incorporate elements of Gastroenterology and Type 2 diabetes. In the journal, Nausea, Anesthesia, Visual analogue scale and Clinical trial are investigated in conjunction with one another to address concerns in Adverse effect research.

Most of the Clinical trial studies addressed also intersect with Intensive care medicine. The work on Tolerability tackled in it brings together disciplines like Placebo and Pharmacokinetics, Cmax. Crossover study and Dosing are some topics wherein Pharmacokinetics research discussed in Clinical Therapeutics have an impact.

The most cited articles from the last journal are:

• Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. (11 citations)
• Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. (10 citations)
• Nonalcoholic Fatty Liver Disease: A Global Perspective. (7 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Clinical Therapeutics (based on the number of publications) are:

• Richard I. Shader (93 papers) published 2 papers at the last edition, 1 less than at the previous edition,
• C. Daniel Mullins (46 papers) absent at the last edition,
• Alan Lyles (45 papers) absent at the last edition,
• Stephen Joel Coons (39 papers) absent at the last edition,
• In-Jin Jang (28 papers) published 1 paper at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Clinical Therapeutics (based on the number of publications) are:

• Pfizer (150 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Merck & Co. (118 papers) absent at the last edition,
• Research Triangle Park (118 papers) published 3 papers at the last edition, 2 more than at the previous edition,
• Eli Lilly and Company (108 papers) published 3 papers at the last edition, 2 less than at the previous edition,
• Veterans Health Administration (94 papers) published 2 papers at the last edition, 3 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 5.70% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 10.99% were posted by at least one author from the top 10 institutions publishing in the journal. Another 8.24% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 23.63% of all publications and 57.14% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Pathways in Clinical Therapeutics

An often overlooked aspect, but equally significant is the variety of career opportunities within Clinical Therapeutics. Many practitioners opt for a research-centric career, contributing significantly to the body of knowledge within internal medicine, pharmacology, anesthesia, and related domains. However, effective translation of this research into practical solutions requires a combination of academic prowess and applicable licensure. Consider Oregon, for example, where fulfilling certain education and certification requirements can open doors to engaging directly with clinical therapeutics applications in a variety of medical environments. Specifically, for those interested in nursing roles within clinical therapeutics, adherence to the stipulated oregon nursing license requirements nursing license education requirements is a crucial factor. Meeting these standards ensures practical competency, and helps aspiring professionals to effectively complement the research findings in the field, enhancing patient care and outcomes. Exploring such professional paths, in tandem with academic research, can bring a holistic understanding of Clinical Therapeutics, pushing the boundaries of what is possible in healthcare.